– Final analysis from the Phase IIIb STASEY study, including data from 193 people with hemophilia A, further support the benefit/risk profile of Hemlibra, with no new safety signals identified – – ...

– There is limited information and treatment guidance on moderate and mild hemophilia A, which can lead to delayed or missed diagnoses of bleeding episodes – – Hemlibra is approved to treat people of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from the ongoing HEMLIBRA ® (emicizumab-kxwh) clinical ...

According to the CDC, hemophilia occurs in about 1 in every 5,000 live births, affecting all races and ethnic groups. There are about 20,000 people with hemophilia in the US, and patients may ...

Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective clotting protein known as factor VIII. Although it is passed down ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced Tuesday that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application or sBLA ...

Genentech, a member of the Roche Group, announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio at the 67 th American ...

Hemlibra is a once-weekly injection for patients with hemophilia A who have developed a resistance to other treatments. The drug’s label contains a black box warning over the risk of severe blood ...

A randomized phase 3 trial designed to assess emicizumab-kxwh for adults and adolescents with hemophilia A without factor VIII inhibitors met its primary endpoint, according to the agent’s ...

– Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from Phase III HAVEN studies, with no new safety signals identified – – STASEY is the largest ...